Trial results for a study investigating virtual reality for vision enhancement in Glaucoma were posted on ClinicalTrials.gov on 2025-12-10, revealing data from a terminated trial that enrolled 22 participants.
Background
Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high pressure in the eye. It is a leading cause of irreversible blindness worldwide. Current treatments typically focus on lowering intraocular pressure to prevent further damage, but there is no cure for existing vision loss. The study aimed to evaluate virtual reality (VR) based visual stimulation as a non-invasive approach for the treatment of blindness arising from Glaucoma and other retinal diseases, specifically through the regeneration of axons of retinal ganglion cells (RGCs).
Trial design
This study, identified as Phase NA, was terminated and enrolled 22 participants. The trial investigated the use of Virtual Reality (VR) based visual stimulation for patients diagnosed with Glaucoma and Vision Disorder. The brief summary indicates the intervention involved VR-based visual stimulation intended to promote regeneration of retinal ganglion cell axons.
Key results
The posted results include several measurements from the "Virtual Reality Stimulation in Patients with Eye Disorders" group:
- For "Change in Visual Field Index (VFI)", mean values were reported as 55.06 percent of visual field (Standard Error: 5.77), 57.66 percent of visual field (Standard Error: 6.86), and 73.5 percent of visual field (Standard Error: 11.08).
- For "Change in Mean Deviation Index (MD)", mean values were reported as -14.69 Decibels (Standard Error: 1.65), -13.33 Decibels (Standard Error: 2.02), and -9.51 Decibels (Standard Error: 3.17).
- For "Retinal Layer Thickness Assessed by Optical Coherence Tomography (OCT)", mean values were reported as 70.67 microns (Standard Error: 4.98) and 67.67 microns (Standard Error: 3.18).
- For "Change in Best Corrected Visual Acuity", mean values were reported as 0.34 logMAR (Standard Error: 0.16) and 0.13 logMAR (Standard Error: 0.10).
What this means
The termination of this study, which enrolled 22 participants, indicates that no definitive conclusions can be drawn regarding the efficacy or safety of virtual reality-based visual stimulation for Glaucoma from this particular trial. While various visual function measurements were posted, including mean values for Visual Field Index, Mean Deviation Index, Retinal Layer Thickness, and Best Corrected Visual Acuity, these results are from a terminated study and lack the context of a completed trial, such as a comparison arm or a clear indication of change from baseline. Therefore, these data do not provide actionable insights for clinicians or patients regarding the potential benefits of this intervention for Glaucoma.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT07071129, titled "Virtual Reality for Enhancement of Vision", were posted on 2025-12-10 on clinicaltrials.gov.